1017 related articles for article (PubMed ID: 28729250)
1. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies.
Krishnan P; Faries P; Niazi K; Jain A; Sachar R; Bachinsky WB; Cardenas J; Werner M; Brodmann M; Mustapha JA; Mena-Hurtado C; Jaff MR; Holden AH; Lyden SP
Circulation; 2017 Sep; 136(12):1102-1113. PubMed ID: 28729250
[TBL] [Abstract][Full Text] [Related]
2. Low-Dose Paclitaxel-Coated Versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease: One-Year Results of the ILLUMENATE European Randomized Clinical Trial (Randomized Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon).
Schroeder H; Werner M; Meyer DR; Reimer P; Krüger K; Jaff MR; Brodmann M;
Circulation; 2017 Jun; 135(23):2227-2236. PubMed ID: 28424223
[TBL] [Abstract][Full Text] [Related]
3. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
Scheinert D; Schmidt A; Zeller T; Müller-Hülsbeck S; Sixt S; Schröder H; Weiss N; Ketelsen D; Ricke J; Steiner S; Rosenfield K
J Endovasc Ther; 2016 Jun; 23(3):409-16. PubMed ID: 27117972
[TBL] [Abstract][Full Text] [Related]
4. Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial.
Schneider PA; Laird JR; Tepe G; Brodmann M; Zeller T; Scheinert D; Metzger C; Micari A; Sachar R; Jaff MR; Wang H; Hasenbank MS; Krishnan P;
Circ Cardiovasc Interv; 2018 Jan; 11(1):e005891. PubMed ID: 29326153
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions.
Laird JA; Schneider PA; Jaff MR; Brodmann M; Zeller T; Metzger DC; Krishnan P; Scheinert D; Micari A; Wang H; Masters M; Tepe G
Circ Cardiovasc Interv; 2019 Jun; 12(6):e007702. PubMed ID: 31195825
[TBL] [Abstract][Full Text] [Related]
6. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial.
Tepe G; Laird J; Schneider P; Brodmann M; Krishnan P; Micari A; Metzger C; Scheinert D; Zeller T; Cohen DJ; Snead DB; Alexander B; Landini M; Jaff MR;
Circulation; 2015 Feb; 131(5):495-502. PubMed ID: 25472980
[TBL] [Abstract][Full Text] [Related]
7. Stellarex drug-coated balloon for treatment of femoropopliteal arterial disease-The ILLUMENATE Global Study: 12-Month results from a prospective, multicenter, single-arm study.
Schroë H; Holden AH; Goueffic Y; Jansen SJ; Peeters P; Keirse K; Ito W; Vermassen F; Micari A; Blessing E; Jaff MR; Zeller T
Catheter Cardiovasc Interv; 2018 Feb; 91(3):497-504. PubMed ID: 29086462
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
[TBL] [Abstract][Full Text] [Related]
9. 12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment.
Steiner S; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
JACC Cardiovasc Interv; 2018 May; 11(10):934-941. PubMed ID: 29730375
[TBL] [Abstract][Full Text] [Related]
10. Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions: 24-Month Results of IN.PACT SFA.
Laird JR; Schneider PA; Tepe G; Brodmann M; Zeller T; Metzger C; Krishnan P; Scheinert D; Micari A; Cohen DJ; Wang H; Hasenbank MS; Jaff MR;
J Am Coll Cardiol; 2015 Dec; 66(21):2329-2338. PubMed ID: 26476467
[TBL] [Abstract][Full Text] [Related]
11. Drug-Coated Balloon Angioplasty Compared With Uncoated Balloons in the Treatment of 200 Chinese Patients With Severe Femoropopliteal Lesions: 24-Month Results of AcoArt I.
Xu Y; Jia X; Zhang J; Zhuang B; Fu W; Wu D; Wang F; Zhao Y; Guo P; Bi W; Wang S; Guo W
JACC Cardiovasc Interv; 2018 Dec; 11(23):2347-2353. PubMed ID: 30448170
[TBL] [Abstract][Full Text] [Related]
12. Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial.
Jaff MR; Rosenfield K; Scheinert D; Rocha-Singh K; Benenati J; Nehler M; White CJ
Am Heart J; 2015 Apr; 169(4):479-85. PubMed ID: 25819854
[TBL] [Abstract][Full Text] [Related]
13. Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery: outcomes from the ILLUMENATE first-in-human study.
Schroeder H; Meyer DR; Lux B; Ruecker F; Martorana M; Duda S
Catheter Cardiovasc Interv; 2015 Aug; 86(2):278-86. PubMed ID: 25708850
[TBL] [Abstract][Full Text] [Related]
14. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty.
Scheinert D; Duda S; Zeller T; Krankenberg H; Ricke J; Bosiers M; Tepe G; Naisbitt S; Rosenfield K
JACC Cardiovasc Interv; 2014 Jan; 7(1):10-9. PubMed ID: 24456716
[TBL] [Abstract][Full Text] [Related]
15. Sustainable Antirestenosis Effect With a Low-Dose Drug-Coated Balloon: The ILLUMENATE European Randomized Clinical Trial 2-Year Results.
Brodmann M; Werner M; Meyer DR; Reimer P; Krüger K; Granada JF; Jaff MR; Schroeder H;
JACC Cardiovasc Interv; 2018 Dec; 11(23):2357-2364. PubMed ID: 30522663
[TBL] [Abstract][Full Text] [Related]
16. Drug-Coated Balloon vs Standard Percutaneous Transluminal Angioplasty for the Treatment of Atherosclerotic Lesions in the Superficial Femoral and Proximal Popliteal Arteries: One-Year Results of the MDT-2113 SFA Japan Randomized Trial.
Iida O; Soga Y; Urasawa K; Saito S; Jaff MR; Wang H; Ookubo H; Yokoi H;
J Endovasc Ther; 2018 Feb; 25(1):109-117. PubMed ID: 29264999
[TBL] [Abstract][Full Text] [Related]
17. No Mortality Signal With Stellarex Low-Dose Paclitaxel DCB: ILLUMENATE Pivotal 4-Year Outcomes.
Lyden SP; Faries PL; Niazi KAK; Sachar R; Jain A; Brodmann M; Werner M; Sood A; Krishnan P
J Endovasc Ther; 2022 Dec; 29(6):929-936. PubMed ID: 35000470
[TBL] [Abstract][Full Text] [Related]
18. Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency: Twelve-Month Results of the DEFINITIVE AR Study.
Zeller T; Langhoff R; Rocha-Singh KJ; Jaff MR; Blessing E; Amann-Vesti B; Krzanowski M; Peeters P; Scheinert D; Torsello G; Sixt S; Tepe G;
Circ Cardiovasc Interv; 2017 Sep; 10(9):e004848. PubMed ID: 28916599
[TBL] [Abstract][Full Text] [Related]
19. Mortality Assessment of Paclitaxel-Coated Balloons: Patient-Level Meta-Analysis of the ILLUMENATE Clinical Program at 3 Years.
Gray WA; Jaff MR; Parikh SA; Ansel GM; Brodmann M; Krishnan P; Razavi MK; Vermassen F; Zeller T; White R; Ouriel K; Adelman MA; Lyden SP
Circulation; 2019 Oct; 140(14):1145-1155. PubMed ID: 31567024
[TBL] [Abstract][Full Text] [Related]
20. Three-Year Sustained Clinical Efficacy of Drug-Coated Balloon Angioplasty in a Real-World Femoropopliteal Cohort.
Torsello G; Stavroulakis K; Brodmann M; Micari A; Tepe G; Veroux P; Benko A; Choi D; Vermassen FEG; Jaff MR; Guo J; Dobranszki R; Zeller T;
J Endovasc Ther; 2020 Oct; 27(5):693-705. PubMed ID: 32583749
[No Abstract] [Full Text] [Related]
[Next] [New Search]